Autologous anti-CD19 agent produces impressive survival improvements
Genetics affect how patients respond
High-risk and real-world patients responded
OncLive summit on hematologic malignancies Oct. 4
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic's approach to the therapy
Anti-CD19 CAR T cell therapy an option for patients with no others
Multicenter study shows survival benefit for patients ≤ 65
Approval may spur competition, cost savings
Novel, large-scale study links ethnicity-specific genes to chronic lymphocytic leukemia